#Bioretec #Finland #Helsinki #Sästopankki #Sp-Rahastoyhtiö

Bioretec Ltd's Recent Shareholding Announcement

On April 29, 2026, Bioretec Ltd announced a key update in accordance with Chapter 9, Section 10 of the Finnish Securities Markets Act. The notification indicated that Sp-Rahastoyhtiö Oy, an investment fund, has surpassed a 5% holding in Bioretec's shares and voting rights. This significant change was reported shortly after the market closed, at 16:40 p.m. EEST.

Details of Shareholding

The total number of shares and voting rights for Bioretec stands at approximately 1.34 billion. Following the notification received from Sp-Rahastoyhtiö, it was confirmed that their current holding now constitutes 8.01% of the company's shares. This marks a notable increase for the fund, reflecting a growing interest in Bioretec’s innovative offerings.

Breakdown of Holdings

The specific figures indicate that Säästöpankki Pienyhtiöt holds 107,531,243 shares directly, representing their stake without any indirect financial instruments affecting the numbers. Comparing this to previous notifications, this does not show any prior holdings, emphasizing the recent acquisition of shares.

About Bioretec

Bioretec Ltd is at the forefront of advancing orthopedic solutions with its pioneering biodegradable implant technologies. The Finnish company has distinguished itself in the industry by developing implants that not only promote bone growth but also accelerate healing processes post-surgery. Their unique products are utilized in approximately 40 countries across the globe.

Innovative Product Lines

Among Bioretec’s cutting-edge solutions is the RemeOs™ product line, crafted from a high-performance magnesium alloy designed to absorb into the body and be replaced by bone, thus negating the need for surgical removal. The first market authorization for RemeOs was attained in the U.S. in March 2023, followed by CE mark approval in Europe in January 2025.

Bioretec also offers the Activa product line, featuring orthopedic implants that are fully bioabsorbable. These products made from a proprietary self-reinforced PLGA have successfully obtained both CE marks and FDA clearances, allowing for a range of applications in both adult and pediatric sectors.

Conclusion

The recent shareholding update signals a positive trajectory for Bioretec Ltd as it continues to innovate and expand its influence in the orthopedic medical device industry. With a focus on patient-friendly solutions, the company is not only shaping the future of orthopedic treatments but is also attracting investor attention, as showcased by the increased stake from Sp-Rahastoyhtiö. To discover more about Bioretec and their impactful innovations, visit their official website at www.bioretec.com.